Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GenSci136 in Healthy Adult Participants
NCT07366866Phase 1Recruiting
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Mar 2026
- Primary completion
- Feb 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in autoimmune disease comparing GenSci136 with Placebo (2 arms). Primary endpoints: Incidence and severity of treatment-emergent adverse events and Incidence and severity of serious adverse events. Started Mar 2026; status: recruiting.
02
Drugs
GenSci136
03
Conditions
autoimmune disease
Beyond the preview
Go deeper on NCT07366866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07366866.